SCHEMBL4035404

SCHEMBL4035404

COc1ccc(CC(=O)N2CCN(S(=O)(=O)c3cccc4cccnc34)C(C(=O)NC(c3ccccc3)c3ccccc3)C2)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.55
ALDH1A1 P00352 5/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
MAPK1 P28482 3/20 0.51
LMNA P02545 2/20 0.50
HSP90AA1 P07900 1/20 0.50
HPGD P15428 1/20 0.48
ALOX15 P16050 2/20 0.48
HTT P42858 1/20 0.48
HSD17B10 Q99714 1/20 0.48
MMP1 P03956 1/20 0.46
MMP3 P08254 1/20 0.46
MMP7 P09237 1/20 0.46
MMP9 P14780 1/20 0.46
MMP13 P45452 1/20 0.46
MAPT P10636 4/20 0.46
TSHR P16473 2/20 0.45
POLB P06746 2/20 0.45
GFER P55789 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4036850 0.91 ALDH1A1 (0.52) GAAALDH1A1SMN1; SMN2MAPK1LMNA
SCHEMBL4032496 0.89 ALDH1A1 (0.51) GAAALDH1A1SMN1; SMN2MAPK1LMNA
SCHEMBL4032606 0.86 GAA (0.57) GAAALDH1A1SMN1; SMN2MAPK1LMNA
SCHEMBL4035407 0.85 MMP1 (0.51) GAAALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL6192513 0.84 ALDH1A1 (0.47) GAAALDH1A1SMN1; SMN2MAPK1LMNA
SCHEMBL4034935 0.83 ALDH1A1 (0.51) GAAALDH1A1SMN1; SMN2MAPK1LMNA
SCHEMBL4032584 0.82 GAA (0.62) GAAALDH1A1SMN1; SMN2MAPK1LMNA
SCHEMBL4038343 0.81 GAA (0.57) GAAALDH1A1SMN1; SMN2MAPK1LMNA
SCHEMBL4034086 0.81 GAA (0.60) GAAALDH1A1SMN1; SMN2MAPK1LMNA
SCHEMBL1384878 0.80 ALDH1A1 (0.55) GAAALDH1A1SMN1; SMN2MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404690-B2 Piperazine-2-carboxamide derivatives MERCK SERONO SA (CH) 2013-03-26 US claimed
EP-1592389-B1 PIPERAZINE-2-CARBOXAMIDE DERIVATIVES SERONO LAB (CH) 2009-04-22 EP claimed
US-20070142391-A1 Piperazine-2-carboxamide derivatives MERCK SERONO SA (CH) 2007-06-21 US claimed
US-8404690-B2 Piperazine-2-carboxamide derivatives MERCK SERONO SA (CH) 2013-03-26 US disclosed
EP-1678169-B1 4-(PYRAZOL-3-YLAMINO)PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2009-07-22 EP disclosed
EP-1592389-B1 PIPERAZINE-2-CARBOXAMIDE DERIVATIVES SERONO LAB (CH) 2009-04-22 EP disclosed
US-20070142391-A1 Piperazine-2-carboxamide derivatives MERCK SERONO SA (CH) 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142391-A1 Piperazine-2-carboxamide derivatives P2RX5, P2RX2, NPY5R GAA 4649/4885ALDH1A1 610/4885SMN1; SMN2 2201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.